Already jumped 55% in 2026, PL Capital sees more returns in Sai Lifesciences shares | Check target, upside

PL Capital believes the company is well positioned to benefit from increasing pharmaceutical outsourcing, a deep commercial pipeline and capacity expansion

MarketNews muestra el titular y el resumen publicados por el medio. El artículo completo se lee en el sitio del editor. (www.livemint.com)